Zydus Cadila looks for endorsement to utilize hepatitis medicate for Covid-19 clinical preliminaries Kumar Jeetendra | May 5, 2020 The nation’s top medication controller, Drug Controller General of India (DCGI), has gotten an application from Zydus Cadila, the leading worldwide pharmaceutical organization in India, to direct clinical preliminary utilizing antiviral medication ‘Pegylated Interferon Alpha-2b’ in grown-up Covid-19 patients. So far in India, the Pegylated Interferon Alpha-2b medication has been utilized for the treatment of …
Mylan’s remdesivir will be available to patients in India at July at Rs.4,800 Kumar Jeetendra | July 6, 2020 Drugmaker Mylan NV said on Monday it secured approval to establish its generic model of Gilead Sciences Inc’s Covid-19 therapy medication remdesivir in India this month at $4,800 per 100 mg vial, as illnesses surge on earth’s third worst-hit country by herpes. The Drug Controller General of India (DCGI) accepted Mylan’s remdesivir model, to be …
Biocon tranquilize gets DCGI gesture for use in moderate to extreme COVID-19 patients Kumar Jeetendra | July 11, 2020 DCGI has vowed to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency usage within India for the cure of cytokine release syndrome (CRS) at moderate to severe ARDS (acute respiratory distress syndrome) patients thanks to COVID-19, Biocon said in a release. It said Itolizumab is your first publication biologic therapy to become approved …
Import licenses for rapid diagnostic units of 3 firms dropped, 15 suspended by DCGI Kumar Jeetendra | July 25, 2020 India’s drug regulator has cancelled the rapid diagnostic kit import licences of 3 firms and suspended that of 15 other people saying the USFDA has eliminated the producers in their listing of coronavirus serology test kits using directions that they shouldn’t be dispersed. The three firms are Cadila Healthcare, MDAAC International and N W Overseas …
India’s Hetero Labs wins endorsement to dispatch COVID-19 medication favipiravir Kumar Jeetendra | July 29, 2020 India’s Hetero Labs Ltd said on Wednesday it received neighborhood regulatory approval to start its own version of antiviral medication favipiravir for the treatment of COVID-19. The drug, priced in 59 rupees (79 cents) each tablet, will probably be Available at drug stores from Wednesday, independently held Hetero explained.
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Kumar Jeetendra | August 20, 2020 India, Mumbai, August 20th , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due …
FDC dispatches 2 variations of Favipiravir in India at Rs 55 for each tablet Kumar Jeetendra | August 25, 2020 Drug firm FDC Ltd on Tuesday said it has established two variants of this COVID-19 drug Favipiravir under the brand names PiFLU and Favenza. The Drug Controller General of India (DCGI) had previously approved the use of Favipiravir, an off patent, oral antiviral drug that’s been demonstrated to quicken clinical healing from COVID-19 patients with …
Optimus Pharma gets DCGI gesture to lead Phase-3 preliminary of COVID-19 antiviral drug Kumar Jeetendra | May 19, 2021 The orally administered drug is being tested for treating mild and moderate infection Optimus Pharma has obtained the approval of the Drug Controller General of India (DCGI) to conduct Phase III clinical trials of orally administered Molnupiravir capsules on patients with mild and moderate Covid-19 infection. In accordance with the clinical trial protocols approved, a …
